
Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers
Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.
Early-onset
In the clinical study supporting clearance, which included 499 plasma samples from cognitively impaired adults, 91.7% of individuals with positive results had amyloid plaques confirmed by PET or cerebrospinal fluid (CSF) testing, and 97.3% of those with negative results had negative PET or CSF findings; fewer than 20% received an indeterminate result. The FDA noted that the test is not intended as a screening or stand-alone diagnostic tool and that results must be interpreted alongside other clinical information.
Allison B. Reiss, MD, an associate professor of medicine at NYU Grossman Long Island School of Medicine, studies AD translationally, from basic molecular mechanisms to clinical care. In a recent Q&A with NeurologyLive®, Reiss discussed the subtle executive-function changes that often delay recognition of early-onset AD, how p-tau217 and amyloid-β ratio blood tests help distinguish AD from frontotemporal dementia (FTD). She talked about her approach to counseling patients and families on nutrition, physical activity, and social engagement, along with the need for trials dedicated to younger patients.
NeurologyLive: What are the early signs of early-onset AD, which are most often overlooked, and how can clinicians recognize them?
Allison B. Reiss, MD: The big problem, which causes a lot of delay in diagnosis and is not really surprising, is that you just do not expect this in a younger person. It’s not high on the list of possibilities, and that’s totally understandable until the signs get fairly undeniable. When we think of AD, we think mostly of a memory problem, and that is a lot of what you see in older patients. But younger-onset AD is defined as younger than 65, sometimes younger than 60, and these are people markedly younger, at an age of productivity, working full time, with a lot of responsibility. This is blindsiding to the clinician and the family because memory is usually pretty well intact. A lot of the personality is intact, and these people are generally pretty healthy because they are younger, so a lot of the complicating factors aren’t there.
What you will see is a very high-functioning person suddenly stumbling in life over things that used to be effortless for them: the loss of executive function, the judgment, the multistep processes, the ability to engage in complex interactions, handling the finances, many things that should be easy for them. A big clue is when someone stops learning. Part of the life of many of us is to be constantly learning, and they can’t take in something new and process it in the same way. Judgment may be off, and many other subtle things come in.
There are a lot of differential diagnoses to consider. Depression is a big one, because when people are depressed, a lot of their cognitive functioning loses its sharpness, but it can be brought back. It’s not the same, because people with young-onset AD are on a decline that is not going to stop; it’s progressive. So the signs may be there, but our ability to really appreciate the implications often lags. That delay is very common, and I’m not sure what one could do about it, because we all have our common-sense instincts about these things.
How are new blood tests changing your approach to evaluating younger patients with cognitive concerns, and where do they fit alongside existing tools?
What I want to say first is that I genuinely think these biomarkers are incredible in their progress, and we have made so much excellent progress. I’m a tough judge, so I don’t say that lightly, because our progress in treatment has not kept up with our progress in our ability to make these fine diagnoses. These tests are really a revolution, and I’m so pleased to see that. I hope we’re going to follow along in developing the treatment.
But these tests are not given as a screening, the way you do a prostate-specific antigen test or the many other tests that we use for screening. They’re not for that purpose. What you must do, especially in younger patients, is the full and comprehensive workup. You have to do the whole physical. You need to go through all of the steps of complete neuropsychological testing. There’s no skipping of the important steps that you have to take to really evaluate somebody.
Where these tests are very helpful is in giving you the cause, the reason. One of the most difficult to distinguish is something we have probably all heard of, FTD. In the early phases, these 2 are very tough to tell apart. But when someone has early-onset AD, it is truly an Alzheimer pathology, and that is what the p-tau217 test and these amyloid-β ratio tests can tell you. When you have everything gathered and then you add that test, it is very helpful in defining which disease is the diagnosis. Imaging and scanning are also very good. I think we’re still doing all of it, but at some point we might not have to do every aspect, or at least not all at the same time, and it is all very expensive. These blood tests, I think, are reaching more and more outside of just the major centers.
I want to stress that the reason you want to know whether it is early AD or FTD is that some of the drug treatments for early AD, like donepezil (Aricept), can make frontotemporal dementia worse. You want to know what you’re dealing with at the pathology level to do the best for treatment. Obviously, you’re not going to use any of the antiamyloid treatments in FTD.
Beyond pharmacologic treatment, how do you counsel patients with early-onset AD and their families on lifestyle factors to help preserve independence?
I want to be clear that I am purely in research, teaching, and speaking to audiences, so I have a lot of contact with families and patients, but not in that office relationship. Doctors will come to me, people will reach out to me directly, and I talk to them. I don’t want to present falsely, but this area is something I’m very passionate about: the community, the advocacy, and reaching people with this advice, because it’s so important not to feel hopeless. It’s so important to know that you do have some agency over these things.
Young patients, as I said, are generally very healthy in other ways, and unfortunately, the disease tends to progress more rapidly in younger patients. Our goal is to keep them as well as possible for as long as possible while we’re trying to find the breakthroughs. We want you to live your best life. We don’t want you to stop living. Especially when you are young, active, and able, keep doing the things you love to do. Don’t sit at home isolating yourself. Get out in the world and be social.
Eat well. The diets that have really come to the fore, and I’m doing a lot of work and writing on nutrition, are the MIND and Mediterranean diets, emphasizing fruits and vegetables and healthy fats. Most important, stay away from processed foods. I say this everywhere: that stuff with 50 chemicals in it that is going to last on your shelf for 2 years is not good for you. Food with a mix of healthy fat, protein, and fiber; eat the rainbow. These are all really good things. Exercise, push yourself, and do the cognitive things that you can do. Physical activity is so important. Sunlight is important, and vitamin D. I see so much low vitamin D; people aren’t getting their vitamin D.
Lifestyle matters. Keep your heart healthy. I just had a big paper out on the heart and the brain and their interaction.2 Your brain needs your heart to pump well and to supply blood, oxygen, and nutrients everywhere. And keep in mind, as you wait and live your life, that we on the other end are working as fast as we can to make breakthroughs.
We also need studies in this particular population. Analyses of results in younger patients are done as a subgroup in the larger group of patients with AD. We’re not specifically targeting, enrolling, and working with these patients. We need to do that to see how the antiamyloid drugs are working for them and what other kinds of treatments might work better for them. The pipeline is there for some, including antiamyloid drugs that have a little more specificity and are less likely to cause brain swelling or bleeding. I feel that the antiamyloid drugs do a little, but we need to be moving to the exciting things that I see for the future. We know that some people with early-onset disease have specific mutations. Eventually, we’ll fix the mutations. We’re going to be able to do regenerative medicine and stem cell therapy. I see what the future will be, and it’s not insoluble. It’s something that can happen.
Transcript edited for clarity.
REFERENCES
1.FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. News release. FDA. May 16, 2025. Accessed November 13, 2026. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
2. Reiss AB, Gulkarov S, Syed U, et al. Heart and Brain: Linking Obesity-Related Inflammation, Cardiovascular Disease and Cognitive Function. J Cardiovasc Dev Dis. 2026;13(10):477. Published 2026 Sep 22. doi:10.3390/jcdd13100477
Related to this article








